By harnessing an AI model, AgnistaBio enables its partners to swiftly

(1)discover highly developable human antibody against target protein of interest, including untargetable proteins, such as GPCRs, and their cryptic epitopes or multiprotein complex specific epitopes.

(2)identify interacting/regulating proteins/enzymes against the target protein and its detail 4D structures for accelerating drug design on a proteome scale in short lead time.